Background: Distant metastases in dogs with cutaneous mast cell tumors (cMCT) are rare and incurable. The aims of this prospective study were to clarify the clinico-pathological features of stage IV cMCTs and to identify possible prognostic factors for progression-free interval (PFI) and survival time (ST).
| MATERIAL AND METHODS

| Inclusion criteria
Members of the Italian Society of Veterinary Oncology (SIONCOV)
were asked to participate to this prospective, multi-institutional study.
Dogs were eligible for recruitment if they had a previously untreated, histologically confirmed cMCT and if they underwent complete staging demonstrating stage IV disease.
Background information recorded for each dog included signalment, body weight, primary tumour description (anatomic location, largest diameter, grade according to the systems of Patnaik and Kiupel, c-kit mutational status), [10] [11] [12] date of initial observation of primary cMCT; clinical stage and substage; date of stage IV diagnosis; site of metastasis; date of surgery or incisional biopsy; histological margins status (for surgically resected cMCTs); other adjuvant treatments;
response of the primary tumour to treatment; response of the metastatic sites to treatment; date of death or last follow-up examination;
cause of death and occurrence of treatment-related toxicity.
Initial staging included history and physical examination, complete blood cell count with differential, serum biochemistry, coagulation profile, histological examination of the cutaneous nodule, histological or cytological examination of regional LN, thoracic radiographs (3 views) and abdominal ultrasound examination or total body computed tomography (TBCT), fine-needle aspirates of liver and spleen regardless of their sonographic appearance, and cytologic examination of bone marrow (BM) obtained from the iliac crest.
The regional LN was defined as the first LN in the expected lymphatic drainage, and was identified either by palpation or by means of ultrasound. Cytologically, LNs or viscera were considered metastatic, if mast cells appeared in clusters or sheets, in very large numbers or atypical on morphology, as previously documented. 3 Histologically, LNs were considered metastatic in the presence of aggregates of mast cells in sinuses (subcapsular, paracortical or medullary) or parenchyma. Giemsa stain was applied in the uncertain cases. Bone marrow was considered infiltrated if mast cells were more than 10% of all nucleated cell, or, if atypical, more than 5% of all nucleated cell, as previously described.
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Written informed consent was obtained from all owners.
| Treatment and response
The type of treatment was at the investigator's personal discretion, and included no therapy, surgery, radiation therapy, chemotherapy, TKI or a combination of these. Depending on treatment, dogs were re-assessed as follows: on a weekly basis if vinblastine was administered, on a monthly basis if lomustine, TKI or no treatment was administered. Physical examination, fine-needle aspiration of any new lesion, and bloodwork were routine elements of each assessment. An abdominal ultrasound was repeated every 1 to 2 months. All responses were defined according to the RECIST criteria. 13 Response was confirmed at least 4 weeks (for complete remission, CR, or partial remission, PR) or 6 weeks (for stable disease, SD) after the first documentation.
Local tumour control was defined as objective local tumour response in addition to freedom from local progression. Distant tumour control was defined as objective distant tumour response in addition to freedom from distant progression.
| Statistical analysis
Progression-free interval (PFI) was calculated from the date of stage IV diagnosis to the date of locoregional and/or distant tumour progression. Survival time (ST) was calculated from the date of stage IV diagnosis to the date of last visit or death. Dogs lost to follow-up or dead due to MCT-unrelated causes were right-censored at the last date of known status or at the date of death, respectively.
The following factors were investigated for prognostic signifi- All dogs underwent complete staging work-up, as previously described; 36 (80%) dogs underwent 3-view thoracic radiographs and abdominal ultrasound, whereas 9 (20%) dogs had a TBCT performed.
All dogs had distant metastatic disease: 22 (48.9%) dogs had splenic and hepatic metastasis, 6 (13.3%) dogs had hepatic metastasis, 3 (6.7%) dogs had splenic metastasis, 3 (6.7%) dogs had metastases in the spleen, liver and non-regional LNs, 3 (6.7%) dogs had metastases in the spleen, liver and BM, 2 (4.4%) dogs had metastases in the spleen and BM, 2 (4.4%) had metastases in the spleen, liver, BM, and non-regional LNs, 1 (2.2%) had metastases in the spleen, liver, BM
and peripheral blood, 1 (2.2%) had splenic, hepatic and pulmonary metastases, 1 (2.2%) had metastases in the spleen and non-regional LNs and 1 (2.2%) had splenic, renal and BM metastases.
Forty-one (91.1%) dogs had also metastasis in the regional LN, while 4 (8.9%) dogs did not. In these 4 dogs, the cMCT was located on the thoracic wall (n = 2), on the vulva (n = 1), and close to a mammary gland (n = 1). Lymph node metastases were confirmed in 30 (73.1%) dogs by means of histopathology, whereas the remaining 11 (26.8%) dogs had only a cytologic diagnosis. Regarding the 4 dogs without LN metastasis, the diagnosis was by means of histopathology in 3 (75%) of them, and by means of cytology in 1 (25%) dog. Visceral metastases were confirmed in all cases by means of cytology.
The median time between the first appearance of cMCT and diagnosis of stage IV disease was 22 days (range, 1 to 96 days). (n = 1), grade 1 (n = 2), 2 (n = 2) and 3 (n = 2) gastro-intestinal side effects, grade 1 (n = 1), 2 (n = 1) and 3 (n = 2) hematologic toxicity, and grade 2 hepatotoxicity (n = 2).
When evaluating the primary MCT, 32 (71.1%) dogs had measurable disease and were therefore assessable for antitumour response. 
| Analysis of prognostic factors
In univariate analysis, factors significantly associated with PFI were:
tumour diameter >3 cm, more than 2 metastatic sites, regional LN metastasis, substage b, and measurable primary tumour (Table 1) .
Factors significantly associated with ST were: tumour diameter >3 cm, more than 2 metastatic sites, regional LN metastases, BM infiltration, substage b and lack of local and distant tumour control (Table 2) .
In multivariate analysis, tumour diameter >3 cm, more than 2 metastatic sites and measurable primary tumour at diagnosis of stage IV disease were still significantly associated with PFI, whereas the factors associated with ST were BM infiltration and lack of local tumour control (Tables 3 and 4) .
Age, sex, weight, anatomic location of the primary tumour, histopathological grade, mutational status, type of treatment and onset of treatment-related toxicity were not significantly associated with either PFI or ST.
| DISCUSSION
In 1 study, approximately 5% of dogs with cMCT had distant metastasis at initial diagnosis, with liver, spleen, BM and distant LNs being the major sites of metastatic involvement. To our knowledge, this is the largest case series of dogs with de novo stage IV cMCT enrolled prospectively, uniformly staged and followed-up.
In this study, dog characteristics were similar to previous publications with median age of diagnosis of 9 years and no sex predilection. 8 In agreement with the literature, Labrador retrievers were over-represented. 14 While Boxers on the whole have been described to carry a better prognosis, 1, 8, 10 in the current study 8 That presence of systemic symptoms is associated with outcome has been already verified. 8, 20 In our study, substage was an indicator of PFI and ST by univariate analysis; however, this relationship was not confirmed by multivariate analysis.
In agreement with previous studies, dogs with cMCTs larger than 3 cm had a significantly shorter PFI and ST. 2, 20, 21 The relationship with PFI was confirmed as independent factor by multivariate analysis. Accordingly, the presence of measurable primary MCT at diagnosis of stage IV disease was associated with significantly shorter PFI Abbreviations: CI, confidence interval; HR, hazard ratio; PFI, progression-free interval; TKI, tyrosine kinase inhibitor. by multivariate analysis. In 18 of these 31 dogs, the measurable tumour represented recurrent disease shortly after a first surgery. As a whole, these results show that bulky disease may not be amenable to efficient local treatment, thereby worsening prognosis.
Metastatic burden also had a negative influence on PFI and ST according to univariate analysis, with more than 2 metastatic sites being associated with a poor outcome, but was not confirmed as independent factor for ST by multivariate analysis.
The concept of the regional LN has been already validated in dogs with cMCT. 5, 22 In general, tumour cells at a specific anatomical site will first drain preferentially to the corresponding LN before reaching other LNs in the same regional basin and then spreading to distant sites, thereby following an orderly progression from local tumour growth at the primary site to the regional LN, followed by distant metastatic dissemination. 23 As a result, close examination of the regional LN is critical, as this provides valuable clinical information regarding the status of disease progression. [5] [6] [7] Occasionally, cancer cells can spread to the systemic sites alone via the vascular system, thereby skipping the regional LN. Within our series, there was heterogeneity of treatment, as many owners elected not to pursue aggressive approaches to management due to the poor prognosis.
In conclusion, stage IV cMCTs are rare and associated with a poor outcome. Nevertheless, asymptomatic dogs with tumour diameter <3 cm and a low tumour burden, without BM infiltration may be candidates for local treatment plus systemic treatment. Stage IV dogs without LN metastasis may enjoy a surprisingly prolonged survival.
The achievement of local tumour control seems to be the main predictor of better outcome in dogs with stage IV cMCT. Abbreviations: CI, confidence interval; HR, hazard ratio.
